That SGLT2 inhibitors results in cardioprotection independent of SGLT2 was also supported by a study showing that empagliflozin could lower infarct size followinh a cardiac ischemia-reperfusion insulin in wild-type and SGLT2 knockout animals alike (40). Here, SLC5A2 is linked to myocardial ischemia.